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health impact of letrozole is of interest to health care
systems. Our objective is to estimate the budget and
health impact of adding letrozole to a US managed care
formulary. METHODS: Estimates of increased time on
ﬁrst-line, second-line, and third-line hormone therapy
were based on clinical trial data for letrozole. These para-
meter values, along with demographic, epidemiology, 
and market share data for a hypothetical managed care
organization in the US with 1,000,000 covered lives were
entered into an interactive EXCEL spreadsheet model.
Outcomes included total annual health plan costs for
hormone therapy and for treatment of advanced breast
cancer with and without letrozole; per member per month
increases in costs associated with letrozole on the formu-
lary; and a proxy measure for life expectancy gain with
letrozole on the formulary, increase in average time on
hormone therapy. Input parameter values could be
changed in the model to capture site-speciﬁc characteris-
tics. RESULTS: The average duration of ﬁrst-line therapy
was 16.5 months with letrozole compared to 11.9 months
with tamoxifen based on the clinical trial data. Assuming
market shares of 25% for letrozole as ﬁrst-line hormone
therapy, 37% for second-line, and 20.5% for third-line,
the increase in per-member, per-month costs of adding
letrozole to the formulary was $0.006 and the increase
cost per treated member per month was $8.37. The life
expectancy beneﬁts with letrozole included in the formu-
lary were estimated as an increase of 2.7 months on
hormone therapy per woman starting endocrine therapy.
CONCLUSIONS: Adding letrozole to a managed formu-
lary results in signiﬁcant health beneﬁts at a very low
increase per member per month cost (less than $0.01).
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OBJECTIVES: The purpose of the study was to estimate
the economic burden in ambulatory care of actinic ker-
atosis (AK) and its progressive state squamous cell carci-
noma (SCC) noninvasive, and invasive or metastasized
SCC. METHODS: prevalence study for 1998 of all 
costs associated with the treatment of these cases using
the National Ambulatory Medical Care Survey and an
administrative claims database from selected plans from
a national health care company was conducted. An expert
panel of dermatology and oncology specialists was used
to develop reference cases reﬂecting the different treat-
ment protocols for AK and nonmelanoma skin cancers.
These reference cases were used for case identiﬁcation and
claims extraction as related to treatment pattern for each
disease state. The resulting analytical ﬁle was then used
to calculate the economic burden of illness. The data
show that the number of visits and the cost per visit
increases with age. RESULTS: The total ambulatory care
costs for AK, SCC and basal cell carcinoma (BCC) com-
bined exceed $2.4 billion/year. AK, SCC and BCC are
responsible for over 5 million ofﬁce visits annually. AK
patients average 2.31 visits/year and SCC/BCC patients
average 2.84 visits/year. SCC and BCC share the same
ICD-9-CM diagnosis code, although different in etiology.
BCC has no known precursor lesions while SCC presents
a progressive state of AK. Assuming conservatively that
the per visit costs for BCC and SCC are the same and that
30% of all BCC/SCC cases are SCC, we estimate that the
total ambulatory care costs of AK and its sequel SCC
exceed $1.1 billion/year. These costs are ambulatory costs
only, and do not include outpatient or inpatient treat-
ment. CONCLUSIONS: Ambulatory care spending on





DALTEPARIN IN PATIENTS WITH
MALIGNANCIES
Sura M1,Vorobyov P1,Avxentieva M1, Papsheva V1, Shilova A3,
Momot A3, Barkagan Z4
1Russian Society for Pharmacoeconomics and Outcomes
Research, Moscow, Russia; 3Altay Medical Institute, Barnoul,
Russia; 4Altai Medical University, Barnaul, Russia
OBJECTIVE: To perform pharmacoeconomical analysis
of unfractionated heparin (UFH) versus dalteparin (D) 
for thrombosis prevention in patients with malignancies.
METHODS: Randomized open pharmacoeconomical
study included 99 patients after operative involvement for
cancer of stomach or bowels: 50 in D group and 49 in
UFH group. The efﬁciency of studied drugs was assessed
by monitoring soluble ﬁbrin monomeric complexes
(SFMC) in blood serum that was considered to be a prog-
nostic factor for thromboembolism. Costs included direct
medical expenditures for hospital treatment from payer’s
perspective. RESULTS: Both drugs signiﬁcantly reduced
SFMC after operation, but patients in D group had sig-
niﬁcantly more expressed decrease in the level of SFMC,
than in UFH group (ð = 0.003). In UFH group vs D group
costs for medicines per patient for period of treatment
were signiﬁcantly less (median cost 2849.4 rub. vs.
6066.4 rub.; ð = 0.000) but costs for medical services
were signiﬁcantly higher (median 21,770.0 and 19,765.0
rub; ð = 0.012), mainly because of more subcutaneous
injections per day. CONCLUSION: D therapy leads to
signiﬁcantly more expressed decrease in SFMC level than
UFH in cancer patients. At the same time costs per treat-
ment are equal because high expenditures for drugs are
compensated by less expenditures for injections. So D is
a reasonable alternative to traditional UFH therapy.
